ENDRA Life Sciences Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
ENDRA Life Sciences reported a Q3 2025 net loss of $1.6 million, down from $2.4 million last year. Operating expenses, including R&D costs, decreased. The company is focused on developing its liver fat measurement device and adopting a digital asset treasury strategy. Management aims to secure additional financing and achieve profitability while continuing innovation in medical technology.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments